Ivosidenib companion diagnostic - Agios Pharmaceuticals/Thermo Fisher Scientific
Latest Information Update: 27 Aug 2021
At a glance
- Originator Thermo Fisher Scientific
- Developer Agios Pharmaceuticals; Thermo Fisher Scientific
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Cholangiocarcinoma
Most Recent Events
- 25 Aug 2021 Registered for Cholangiocarcinoma (Diagnosis) in USA (unspecified route)
- 28 Jul 2021 No recent reports of development identified for research development in Cholangiocarcinoma(Diagnosis) in USA
- 18 May 2017 Thermo Fisher Scientific and Agios Pharmaceuticals enter research collaboration to develop Ivosidenib companion diagnostic